B. Riley raised the firm’s price target on Kymera Therapeutics (KYMR) to $117 from $80 and keeps a Buy rating on the shares. The firm says KT-621 demonstrated strong Phase 1b results in moderate to severe atopic dermatitis. The efficacy was observed even in subjects with minimal prior dupilumab exposure and showed no plateauing at 28 days, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $103 from $70 at RBC Capital
- Kymera Therapeutics price target raised to $110 from $65 at Stephens
- Kymera Therapeutics’ KT-621 in dermatitis granted Fast Track Designation by FDA
- Kymera Therapeutics price target raised to $120 from $81 at Mizuho
- Kymera Therapeutics Announces Major Stock Offering